El Mundo on MSN2d
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
STAT1d
HIV self-testing is easy, effective — and underutilized
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
PharmExec2h
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
‘Annual shot to prevent HIV proven safe’
The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
The Lancet2d
The potential for annual long-acting HIV pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
News-Medical.Net on MSN1d
Study reveals an integrated care model for improving outcomes among people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...
Opinion: Harm has been done to inhibit progress combating HIV/AIDS
Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...
The Washington Informer1d
Empowering Women and Girls: Advancing HIV Prevention
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...